

# Influența microbiomului intestinal asupra efectelor adverse ale chimioterapiei în patologia oncologică

*Dr. Radu-Dumitru Dragomir*

*Medic Specialist – Oncologie Medicală*

*Centrul de Oncologie OncoHelp, Timișoara*

# The influence of the gut microbiome on the adverse effects of chemotherapy in oncological pathology


*Dr. Radu-Dumitru Dragomir*

*Medical Oncology Specialist*

*OncoHelp Cancer Center, Timișoara*


# Chemotherapy adverse events (AE)

- AEs → main drawback of chemotherapy
- Up to 87% of people experienced at least one AE during and after chemo
- Common AEs: nausea and vomiting, diarrhea, constipation, mucositis, CTX induced peripheral neuropathy (CIPN), fatigue etc.
- Challenges:
  - implementation of effective strategies for preventing and managing AE's;
  - minimising health service costs and the financial burden for patients and their families;
  - developing of effective biomarkers that have been developed to predict and/or proactively manage CTX-induced AEs



- facilitation of drug efficacy;
- abrogation and compromise of anticancer effects;
- mediation of toxicity;

*Irinotecan*



# The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity

Wing Lam<sup>1</sup>, Scott Bussom<sup>1</sup>, Fulan Guan<sup>1</sup>, Zaoli Jiang<sup>1,2</sup>, Wei Zhang<sup>1</sup>, Elizabeth A. Gullen<sup>1</sup>, Shwu-Huey Liu<sup>2</sup> and Yung-Chi Ch...

+ See all authors and affiliations

*Science Translational Medicine* 18 Aug 2010:


Vol. 2, Issue 45, pp. 45ra59

DOI: 10.1126/scitranslmed.3001270

## PHY906

- *Glycyrrhiza uralensis*
- *Paeonia lactiflora*
- *Scutellaria baicalensis*
- *Ziziphus jujuba*

biotransformation via bacterial  $\beta$ -glucuronidase






Restorative effect on the intestinal epithelium



Reduced irinotecan gastro-intestinal toxicity

Cancer Therapy: Preclinical

**Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial  $\beta$ -Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity**Ren Kong<sup>1</sup>, Timothy Liu<sup>1</sup>, Xiaoping Zhu<sup>1</sup>, Syed Ahmad<sup>3</sup>, Alfred L. Williams<sup>3</sup>, Alexandria T. Phan<sup>2</sup>, Hong Zhao<sup>1</sup>, John E. Scott<sup>3</sup>, Li-An Yeh<sup>3</sup>, and Stephen T.C. Wong<sup>1,2</sup>**Effects of Amoxapine on CPT-11-induced diarrhea, survival and tumor growth in tumor-bearing mice**




## The Inhibitory Effect of Ciprofloxacin on the $\beta$ -Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G


Takaaki Kodawara<sup>1</sup>, Takashi Higashi<sup>1</sup>, Yutaka Negoro<sup>1</sup>, Yukio Kamitani<sup>1</sup>, Toshiaki Igarashi<sup>1</sup>, Kyohei Watanabe<sup>1</sup>, Hitoshi Tsukamoto<sup>1,2</sup>, Ryoichi Yano<sup>1</sup>, Mikio Masada<sup>3</sup>, Hiromichi Iwasaki<sup>1,2</sup> and Toshiaki Nakamura<sup>1</sup>

<sup>1</sup>Department of Pharmacy, University of Fukui Hospital, Eiheiji-cho, Yoshida-gun, Fukui-ken, Japan, <sup>2</sup>Infection Control and Prevention, University of Fukui Hospital, Eiheiji-cho, Yoshida-gun, Fukui-ken, Japan and <sup>3</sup>Osaka University of Pharmaceutical Sciences, Takatsuki-shi, Osaka-fu, Japan

(Received 11 September 2015; Accepted 20 October 2015)



The analysis of the kinetics of the  $\beta$ -glucuronidase-mediated deconjugation of SN-38-G to SN-38 in the presence of inhibitors.



The effects of various antibacterial drugs on the deconjugation of SN-38-G to SN-38.

*Methotrexate*

RESEARCH ARTICLE | FEBRUARY 15 2015

## TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine

Magdalena Frank; Eva Maria Hennenberg; Annette Eyking; Michael Rünzi; Guido Gerken; Paul Scott; Julian Parkhill; Alan W. Walker; Elke Cario 





[+ Author & Article Information](#)

*J Immunol* (2015) 194 (4): 1983–1995.



<https://doi.org/10.4049/jimmunol.1402481> [Article history](#) 

- WT, TLR2 KO, MD-2 KO and TLR2/MD-2 dKO murines
- Cultures of human duodenal pinch biopsies ex vivo


# Genetic deletion of TLR2, but not MD-2, in mice results in severe chemotherapy-induced intestinal mucositis



# Gut microbiota depletion results in increased small intestinal chemotoxicity in WT mice, which is alleviated by TLR2 ligand supplementation



# Treatment with the TLR2 agonist PCSK prevents chemotherapy-induced cytotoxic damage in human duodenal lamina propria mononuclear cells of patients



*Oxaliplatin*

[Published: 17 July 2017](#)

## **Gut microbiota is critical for the induction of chemotherapy-induced pain**

[Shiqian Shen](#) , [Grewo Lim](#), [Zerong You](#), [Weihua Ding](#), [Peigen Huang](#), [Chongzhao Ran](#), [Jason Doheny](#), [Peter Caravan](#), [Samuel Tate](#), [Kun Hu](#), [Hyangin Kim](#), [Michael McCabe](#), [Bo Huang](#), [Zhongcong Xie](#), [Douglas Kwon](#), [Lucy Chen](#) & [Jianren Mao](#) 

[Nature Neuroscience](#) **20**, 1213–1216 (2017) | [Cite this article](#)


**10k** Accesses | **151** Citations | **70** Altmetric | [Metrics](#)

Lim, G., You, Z. et al. Gut


→ abx mice (fed water containing antibiotics), H2O mice (fed regular water),  
SPF (specific pathogen-free) and GF (germ-free) mice



# The gut microbiota promotes the development of oxaliplatin-induced mechanical hyperalgesia




- Lipopolysaccharides → bacterial wall component
- LPS is a ligand of Toll-like receptor 4 (Tlr4)



- These results suggest that gut microbiota influenced the development of mechanical hyperalgesia following oxaliplatin therapy through an LPS–TLR4 pathway – hematopoietic cells

[Published: 06 May 2021](#)


## Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin

[Wenzhen Yuan](#), [Xingpeng Xiao](#), [Xuan Yu](#) , [Fuquan Xie](#), [Pengya Feng](#), [Kamran Malik](#), [Jingyuan Wu](#), [Ze Ye](#), [Peng Zhang](#) & [Xiangkai Li](#) 

[Probiotics and Antimicrobial Proteins](#) **14**, 60–71 (2022) | [Cite this article](#)


- Two probiotic strains, *B. mesentericus* TO-A and *S. faecalis* T-110, were selected from the composition of the BIO-THREE tablets
- It has been reported that the use of BIO-THREE is safe and effective for the treatment of ulcerative colitis

Oxaliplatin had a negative effect on the small intestine, which was counteracted by the probiotics (CK levels of TNF- $\alpha$ )




# The abundance of *Prevotella* and *Bacteroides* was significantly changed by treatment with oxaliplatin


(c)




(d)



(b)



# *Human clinical trials*

ORIGINAL ARTICLE | [Open Access](#) | 

## Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer

Zhe Zhao, Kailun Fei, Hua Bai, Zhijie Wang, Jianchun Duan, Jie Wang 

- 64 patients with locally advanced and advanced lung cancer
- 1<sup>st</sup> line chemotherapy:
  - PEM combined with CDDP or CBP ± bevacizumab for patients with lung ADK
  - PTX or GEM in combination with CDDP or CBP for lung SCC
  - ETO in combination with CDDP or CBP for SCLC
  - PTX combined with CDDP or CBP for lung adenosquamous carcinoma
- Analysis of baseline stool samples before chemotherapy treatment, through metagenomics of the gut microbiota


# AEs recorded

Characteristics	No. of patients (N = 64)	%
Myelosuppression	64	
0	4	6.25%
I	21	32.81%
II	18	28.125%
III	14	21.875%
IV	7	10.94%
Gastrointestinal reaction	64	
0	6	9.375%
I	40	62.5%
II	14	21.875%
III	4	6.25%
IV	0	0



# AEs after chemo

- ↑ *Bacteroides nordii*
- ↑ *Ruminococcus sp\_5\_1\_39BFAA*
- ↓ *Gardnerella vaginalis*




RESEARCH


Open Access

# Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer



Zuo Fei<sup>1</sup>, Yin Lijuan<sup>2</sup>, Yang Xi<sup>3</sup>, Wu Wei<sup>1</sup>, Zhong Jing<sup>4</sup>, Da Miao<sup>5</sup> and Han Shuwen<sup>6\*</sup> 

- 17 patients were finally included in the study
  - CID+ = 4 (CID grade 2)
  - CID- = 13
- Stool samples of the patients were collected in the 2 weeks after the 8 cycles of chemotherapy



- **CID**

- ↓ a-diversity
- ↑ Proteobacteria
- ↑ Enterobacteriales
- ↑ Gammaproteobacteria
- ↑ Enterobacteriaceae
  - ↑ Klebsiella
- ***Klebsiella pneumoniae* was the most predominant species (31.22%) among the gut microbiome**

- **NO CID**

- ↑ Clostridiales,
- ↑ Clostridia
- ↑ Ruminococcaceae
- ↑ Bacteroidetes
- ↑ Bacteroidia
  - ↑ Bacteroidales
  - ↑ Bacteroides
  - ↑ Bacteroidaceae

## Perspectives

- Pharmacomicrobiomics?
- Gut microbiota as a biomarker for outcomes?
- FMT?
- Dietary interventions?
- Probiotics, prebiotics and synbiotics?
- Antibiotics, ecology and synthetic engineering?



Thank you!